Idexx Laboratories Profile
Key Indicators
- Authorised Capital ₹ 7.92 Cr
as on 24-10-2024
- Paid Up Capital ₹ 7.92 Cr
as on 24-10-2024
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 10.68%
(FY 2023)
- Profit 36.39%
(FY 2023)
- Ebitda 22.71%
(FY 2023)
- Net Worth 9.50%
(FY 2023)
- Total Assets 41.46%
(FY 2023)
About Idexx Laboratories
The Corporate was formerly known as Idexx Laboratories India Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.92 Cr and a paid-up capital of Rs 7.92 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nilesh Shah, Jeffery Chadbourne, Willard Jr, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999KA2016FTC097855
- Company No.
097855
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
17 Nov 2016
- Date of AGM
10 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Idexx Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Willard Jr  | Director | 28-Apr-2018 | Current |
| Lily Lu | Director | 22-Feb-2019 | Current |
| Jeffery Chadbourne | Director | 28-Apr-2018 | Current |
Nilesh Shah  | Director | 18-Sep-2017 | Current |
Financial Performance and Corporate Structure Insights of Idexx Laboratories.
Idexx Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.68% increase. The company also saw a substantial improvement in profitability, with a 36.39% increase in profit. The company's net worth moved up by a moderate rise of 9.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Idexx Laboratories?
In 2023, Idexx Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Millennium Consulting (India) Private Limited
Active 13 years 8 monthsNilesh Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Idexx Laboratories?
Idexx Laboratories has a workforce of 11 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Idexx Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Idexx Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
